tbuckley/cabot-search huggingface dataset:
Recommended core outcome instruments for health‐related quality of life, long‐term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting
Authors: K.S. Thomas, C.A. Apfelbacher, J.R. Chalmers, E. Simpson, P.I. Spuls, L.A.A. Gerbens, H.C. Williams, J. Schmitt, M. Gabes, L. Howells, B.L. Stuart, E. Grinich, T. Pawlitschek, T. Burton, L. Howie, A. Gadkari, L. Eckert, T. Ebata, M. Boers, H. Saeki, T. Nakahara, N. Katoh
Journal: British Journal of Dermatology (2020)

The Harmonising Outcome Measures for Eczema (HOME) initiative has established a core outcome set of domains for atopic eczema (AE) clinical trials. Previous consensus meetings have agreed on preferred instruments for clinician‐reported signs (Eczema Area and Severity Index, EASI) and patient‐reported symptoms (Patient‐Oriented Eczema Measure, POEM). This paper reports consensus decisions from the HOME VII meeting. To complete the core outcome set for AE by agreeing on core outcome instruments for the domains of quality of life (QoL), long‐term control and itch intensity. A face‐to‐face consensus meeting was held in Tokyo, Japan (8–10 April 2019) including 75 participants (49 healthcare professionals/methodologists, 14 patients, 12 industry representatives) from 16 countries. Consensus decisions were made by presentations of evidence, followed by whole and small group discussions and anonymous voting using predefined consensus rules. It was agreed by consensus that QoL should be measured using the Dermatology Life Quality Index (DLQI) for adults, the Children’s Dermatology Life Quality Index (CDLQI) for children and the Infant’s Dermatology Quality of Life Index (IDQoL) for infants. For long‐term control, the Recap of Atopic Eczema (RECAP) instrument or the Atopic Dermatitis Control Test (ADCT) should be used. Consensus was not reached over the frequency of data collection for long‐term control. The peak itch numerical rating scale (NRS)‐11 past 24 h was recommended as an additional instrument for the symptom domain in trials of older children and adults. Agreement was reached that all core outcome instruments should be captured at baseline and at the time of primary outcome assessment as a minimum. For now, the core outcome set for clinical trials in AE is complete. The specified domains and instruments should be used in all new clinical trials and systematic reviews of eczema treatments.
Phase II study: Induction chemotherapy and transoral surgery as definitive treatment (Tx) for locally advanced oropharyngeal squamous cell carcinoma (OPSCC): A novel approach.
Authors: Robert S. Siegel, Hind Rafei, Arjun Joshi, Reza Taheri, Naja Fousheé, Nader Sadeghi
Journal: Journal of Clinical Oncology (2018)

6004 Background: The standard of care for OPSCC includes chemoradiation (CRT) or surgery with adjuvant radiation (RT). However, RT is associated with significant life long morbidity. We assessed the efficacy of a two-drug induction regimen, followed by transoral robotic assisted surgery (TORS) & neck dissection for locally advanced OPSCC. Methods: This is an IRB approved single-arm phase II study for untreated stage III or IVA (AJCC 7th edition) OPSCC patients (pts) with an ECOG < 2 and GFR >50 cc. Induction chemotherapy consisted of cisplatin 75 mg/m2 and docetaxel 75 mg/m2 every 21 days for 3 cycles. Tumor shrinkage was examined after each cycle. If the primary tumor was ≥ 80% smaller, pts underwent TORS and neck dissection(s). At post-op visits, flexible laryngoscopy, blood tests, and imaging with PET/CT and/or MRI were done. Short and long term toxicity, progression-free survival, overall survival, and quality of life (QOL) were evaluated. Results: Twenty pts were treated, nineteen were male, 17 were Caucasian, and 19 were HPV+. Median age at diagnosis was 57. Tumors involved the tonsil (13 pts) and base of tongue (7 pts). Three pts were stage III, and 17 were stage IVA. Tumor size was reduced by 53.4%, 80% and 90.5% after the 1st, 2nd and 3rd induction cycles respectively. Pathologic CR of the primary site occurred in 15 pts and CR among LN neck dissections occurred in 13 pts. Four pts were given dose-reduced chemo and one pt was changed to carboplatin per protocol because of renal dysfunction. Pre vs post tx QOL scores did not change. At a mean follow-up of 21 months (range 7.6 to 32.1), 18 pts are alive and NED. Three pts recurred a mean of 2.2 months after surgery, and were treated with salvage CRT. Two pts died of metastatic disease, the third is alive and well. All 3 pts had positive LN (9 LN, 3 LN and 1 LN) at surgery. Conclusions: Cisplatin + docetaxel followed by TORS & neck resections appears to be an effective model for the definitive treatment for OPSCC, while avoiding the adverse effects of RT. Clinical trial information: NCT02760667.
THE PROPOSED CONSTITUTION AND BY-LAWS FOR STATE SOCIETIES.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Guidelines for Interactions With Pharmaceutical Companies
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A randomised controlled trial to evaluate both the role and optimal fractionation of radiotherapy in the conservative management of early breast cancer.
Authors: D Spooner, DD Stocken, S Jordan, S Bathers, JA Dunn, C Jevons, M Morrison, G Oates, R Grieve
Journal: Cancer Research (2009)

Abstract Abstract #5125 Background: Postoperative radiotherapy is routinely used in early breast cancer using 50Gy in 25 daily fractions (Long). Both the role of radiotherapy and shorter regimens require validation.&amp;#x2028; Methods: Patients with clinical stage 1 and 2 disease were randomised to receive immediate postoperative (RT) or delayed salvage treatment (No RT). Patients receiving RT were further randomised to Long or Short (40Gy in 15 daily fractions) regimens. The primary outcome measure was time to first relapse. Reported results are at median follow up of 16.9 years (IQR 15.4 - 18.8).&amp;#x2028; Results: 707 women were recruited between 1985 and 1992: median age 59 years (range 28-80), 72% post menopausal, median tumour size 2.0cms (range 0.12-8.0). 271 patients have relapsed: 110 RT, 161 No RT. Site of first relapse was reported as 158 (64%) locoregional and 87 (36%) distant. Immediate RT significantly reduced the risk of relapse by 42% (HR=0.58 (95%CI: 0.45, 0.73), chi2LR=20.40, p&amp;lt;0.001) consistent across all prognostic subgroups. Immediate RT reduced the risk of locoregional relapse by 65% (HR=0.35 (95%CI: 0.25, 0.47), (chi2LR=40.47, p&amp;lt;0.001). No difference in relapse site, or frequency was seen between the 2 fractions. No differences were seen in overall or breast cancer specific survival.&amp;#x2028; Discussion: With a median follow-up of 17 years, this study confirms the benefit for patients with early breast cancer receiving radiotherapy. We conclude that a radiotherapy schedule of 40 Gy in 15 daily fractions is a safe, efficient and effective regime at least as good as the international conventional regime of 50 Gy in 25 daily fractions. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 5125.
PATH-54. Gli3 INDUCES NEURONAL DIFFERENTIATION IN WNT- AND SHH- ACTIVATED MEDULLOBLASTOMA
Authors: Manabu Natsumeda, Hiroaki Miyahara, Junichi Yoshimura, Takanori Nozawa, Yoshihiro Tsukamoto, Takafumi Wataya, Charles Eberhart, Hitoshi Takahashi, Akiyoshi Kakita, Yukihiko Fujii
Journal: Neuro-Oncology (2017)

We have previously investigated the expression of Gli3, a downstream target of the Sonic Hedgehog pathway, which main function is to suppress Gli1/2 in medulloblastomas. We found that Gli3 is associated with neuronal and glial differentiation in desmoplastic / nodular (D/N) type medulloblastomas (Miyahara et al., Neuropathology, 2013). In the present study, we investigated the relationship between Gli3 expression and molecular subgroup of medulloblastoma. Thirty-five medulloblastomas treated at Department of Neurosurgery, Niigata University between 1982 and 2013 were retrospectively studied. Molecular classification into 4 subgroups (WNT-activated, SHH-activated, Group 3 and Group 4) was performed using Nanostring. HE and NeuN, GFAP, β-catenin, GAB-1, and YAP-1 immunohistochemistry was performed. Furthermore, Gli3 and Gli1 expression in each molecular subgroup was assessed in the public data base “R2”. Nanostring was feasible in 34 cases. Four cases were classified as WNT- activated, 5 cases as SHH-activated, 4 cases as Group 3 and 21 cases as Group 4. Gli3 was positive in 17 cases, including all 4 (100%) WNT-activated cases and 3 (60%) SHH-activated cases. R2 database analysis confirmed that Gli3 was elevated in WNT- and SHH-activated medulloblastoma. Gli1 was elevated in SHH-activated cases but suppressed in WNT-activated cases. IHC analysis revealed that Gli3 was elevated inside the nodules of D/N type medulloblastoma. Neuronal differentiation was seen in these nodules. These results suggest that Gli3 is elevated inside the nodules of SHH-activated medulloblastoma, whereas in WNT-activated cases, Gli3 suppresses HH signaling in the entire tumor.
Mesenteric phlebosclerosis
Authors: A. Oshima, S. Ito, Y. Abe, T. Uchiyama, H. Iida, H. Endo, K. Hosono, Y. Sakamoto, K. Fujita, M. Yoneda, H. Takahashi, T. Koide, C. Tokoro, A. Goto, M. Inamori, N. Kobayashi, K. Kubota, S. Saito, A. Nakajima
Journal: Endoscopy (2010)

Phlebosclerosis is a rare cause of chronic mesenteric ischemia, and is characterized by thickening of the colonic wall with calcification of the affected veins. Phlebosclerosis as a disease entity has been recently proposed by Iwashita et al [1]. Fewer than 100 cases have been reported to date, and most are from Japan. We present a case of chronic ischemic colonic lesions caused by phlebosclerosis.
Poster Discussions
Authors: J. López, M. Jiménez, J. Peláez, M. A. Arce, M. J. Asensio, F. Arnalich, A. Hernanz, J. Zweigner, H. -J. Gramm, N. Lamping, A. Kopf, A. Asmus, R. R. Schumann, J. Zimmermann, H. Meinhold, W. Beier, K. Wegscheider, M. Murphy, A. Catania, M. Cutuli, L. Garofalo, F. Valenza, J. M. Lipton, D. Berger, E. Boelke, N. Hiki, R. Lissner, A. Arnold, F. Hausmann, M. Seidelmann, H. G. Beger, D. Berger, H. D. Braunmueller, E. Bōlke, U. Schmidt, S. Ott, H. Seidelmann, C. Bohuon, J. Raymond, M. Assicot, F. Moulin, M. Bergeret, P. Lebon, D. Gendrei, M. Lantéri-Minet, J. Y. Scoazec, C. Dosquet, P. Beyne, H. Voitot, J. M. Mencia-Huerta, P. Lettéron, D. Lebrec, C. H. Lehmann, K. Egerer, A. Georgiew, M. Weber, W. J. Kox, F. M. Brunkhorst, Z. F. Forycki, W. Beier, J. Wagner, S. E. Orfanos, A. Armaganidis, H. Bardouniotou, I. Mavrommati, J. D. Catravas, J. Economidou, Ch. Roussos
Journal: Intensive Care Medicine (1996)
Editorial: Cell life and death in human tumours.
Journal: BMJ (1976)

Cell life and death in human tumours "Active, aggressive, rapidly proliferating" are terms that appear in many histopathologists' reports but bear little relation to the nature of the tumour or its probable sensitivity to treatment.This emotive language tends to perpetuate the myth of the proliferation of cancer cells outstripping their normal counterparts and reflects a lack of appreciation of the behaviour of tumour cell populations by many concerned with cancer treatment.
Syllabus of Lectures on the Practice of Surgery.
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Diagnostic and therapeutic technology assessment. Gastric restrictive surgery
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Immunobiology of Myasthenia Gravis, Experimental Autoimmune Myasthenia Gravis, and Lambert-Eaton Syndrome
Authors: J Lindstrom
Journal: Annual Review of Immunology (1985)

Exhausted CD8 T (Tex) cells are a distinct cell lineage that arise during chronic infections and cancers in animal models and humans. Tex cells are characterized by progressive loss of effector functions, high and sustained inhibitory receptor expression, ...Read More
Tool for Learning Disabilities
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Right ventricular function is a predictor of outcome in patients with left ventricular dysfunction after myocardial infarction. The survival and ventricular enlargement trial Leonardo Zornoff, Hicham Skali, Martin St. John Sutton, Jean Rouleau, Gervasio Lamas, Sandra Lewis, Ted Plappert, Jacques Rouleau, Lemuel Moye, Marc Pfeffer, Scott Solomon. Brigham and Women's Hospital, Boston, MA
Journal: Journal of the American College of Cardiology (2001)
PLoS Medicine Issue Image | Vol. 7(1) January 2010
Journal: PLoS Medicine (2010)

Recent high-impact collisions between health research and politics include a US Senate vote to disregard updated US Preventive Services Task Force guidelines for breast cancer screening, and the UK Home Secretary's dismissal of drug abuse advisor Prof. David Nutt. Considering the prospects for unbiased comparative effectiveness research in light of such events, the PLoS Medicine Editors argue that "evidence-based medicine deserves better than a push out of the frying pan of partisan politics into the fire of vested interests," and urge politicians to remember that "society encompasses not only the corporate engines of economic growth and decline, but also individuals whose lives depend on the quality of health care data." Image Credit: Chris Pichado
HOFRAT PROFESSOR DR. GUSTAV RIEHL (1855-1943)
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Blood pressure during normal daily activities, sleep, and exercise. Comparison of values in normal and hypertensive subjects
Authors: T. G. Pickering
Journal: JAMA (1982)

Blood pressure (BP) readings were taken every 15 minutes using a noninvasive ambulatory BP recorder during 24 hours in 25 subjects with normal BP, 25 with borderline hypertension, and 25 with established essential hypertension. Readings were analyzed for four situations: (1) physician's office, (2) work, (3) at home, and (4) asleep. Treadmill exercise tests were also performed on a separate occasion with the Bruce protocol. The 24-hour recording in all three groups showed the highest BPs at work and the lowest during sleep. The situational BP changes were generally similar, but both hypertensive groups differed from normal subjects in that they showed consistently higher BPs in the physician's office than at home, whereas normal subjects showed little difference. During exercise, the hypertensive groups showed a similar rise of systolic pressure to that of normal subjects. Pressures recorded in the physician's office gave good predictions of the average 24-hour pressure in normal and established hypertensive subjects, but not in the borderline group; in such patients, 24-hour monitoring may be of particular value in establishing the need for treatment. (<i>JAMA</i>1982;247:992-996)
Forensic psychiatry—friend of the court
Journal: JAMA (1979)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal